Mountain Valley MD Holdings updates on "encouraging" progress in its pre-clinical trial portfolio

Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) has provided new insight into its progress on a selection of ongoing pre-clinical trials. "Receiving early feedback confirming the ability to safely inject Ivectosol 1% across poultry, swine, goat and cattle our initial animal trials is very encouraging and validates the pathway we are pursuing in human applications such as oncology and COVID-19," Mountain Valley MD CEO Dennis Hancock told investors in a statement.  "I am very proud of the team and our research partners for this incredible progress across multiple lanes of innovation.  We couldn't be more honoured to drive forward this important work," he added. READ: Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials The Canadian biotechnology company said it had received cold chain ELISA data from the US Food and Drug Administration Polio Research lab and is currently coordinating an analysis review session with the regulator. Other highlights from Mountain Valley MD's trial portfolio include: A recent Bio Safety Level 4 lab study of coronavirus (COVID-19) viral clearance in transgenic mice is expected to deliver results early next week It has filed the Porous Aluminum Nano-Structured Adjuvant patent to support its advanced vaccine dose sparing work, with results from the associated study expected in late May or early June Husbandry animal trials have started in Canada and Bangladesh to validate the superiority of its injectable solubilized Ivermectin technology, Ivectosol 1%, versus current commercially available forms to treat a broad category of animal parasites, with results from both studies expected in June It has filed the cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens Separate pre-clinical trials for triple-negative breast cancer, metastatic melanoma and Lewis Lung Carcinoma are being conducted and the company anticipates preliminary results for the studies later in June Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology for macrocyclic lactones. Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas